Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in PsoriaticPatients Previously Treated With Foam Vehicle

Giacomo Caldarola; Enrico Bocchino; Eleonora De Luca; Alessandra D'Amore; Niccolò Gori; Clara De Simone; Ketty Peris

doi:10.5826/dpc.1503a5696

Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in PsoriaticPatients Previously Treated With Foam Vehicle

Authors

Giacomo Caldarola Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Enrico Bocchino Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy https://orcid.org/0000-0001-9208-8887
Eleonora De Luca Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Alessandra D'Amore Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Niccolò Gori Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Clara De Simone Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Ketty Peris Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy 2 UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

Keywords:

Psoriasis treatment, Topical therapy, Calcipotriene/Betamethasone dipropionate, Patient preference, Polyaphron Dispersion (PAD™) technology

Abstract

Introduction: Topical therapy is the first-line treatment for mild to moderate psoriasis, and guidelines recommend the combination of calcipotriene and betamethasone dipropionate (Cal/BD) as the preferred option, with its wide range of available formulations.

Objective: The aims of this study are to assess the preference for Cal/BD cream in a group of patients previously treated with Cal/BD foam spray and, additionally, to evaluate their satisfaction with the treatment.

Method: We conducted a prospective observational study on psoriatic patients treated with Cal/BD cream who had used Cal/BD foam in the previous three months. After 4 weeks of treatment, the comparison between the cream and the previous treatment with the foam has been evaluated by Patient Preference Adherence Questionnaire (PPQ) questionnaire. Additionally, patient satisfaction was evaluated through Psoriasis Treatment Convenience Scale (PTCS) and Topical Therapy Adherence Questionnaire (TTAQ).

Results: Thirty patients with mild to moderate psoriasis were enrolled. After 28 days of treatment, PASI, BSA, and DLQI scores showed significant improvement (p<0.05). According to the Patient Preference Adherence Questionnaire (PPQ), 24/30 patients found Cal/BD cream overall preferable to the Cal/BD foam formulation. Moreover, PTCS and TTAQ questionnaires found a very high level of satisfaction with the cream.

Conclusion: These findings suggest that Cal/BD cream represents a valuable therapeutic option for patients starting topical treatment, thanks to its high cosmetic acceptability.

References

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021 Apr 3;397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6. PMID: 33812489.

Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S14-9. Epub 2015 Oct 15. PMID: 26472560.

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med. 2025 Apr 17;22(4):e1004591. DOI: 10.1371/journal.pmed.1004591. PMID: 40245096; PMCID: PMC12052210.

Ibba L, Di Giulio S, Gargiulo L et al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024 Dec;35(1):2425029. DOI: 10.1080/09546634.2024.2425029. Epub 2024 Nov 7. PMID: 39510528.

Thurston AW Jr, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. Am J Clin Dermatol. 2023 Mar;24(2):315-324. DOI: 10.1007/s40257-022-00741-9. Epub 2022 Nov 24. PMID: 36422852; PMCID: PMC9968262.

Armstrong AW, Bissonnette R, Chovatiya R et al. Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis. Cutis. 2024 Oct;114(4):122-127. DOI: 10.12788/cutis.1112. PMID: 39621574.

Chiricozzi A, Pimpinelli N, Ricceri F et al. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatol Ther. 2017 Nov;30(6). DOI: 10.1111/dth.12549. Epub 2017 Sep 20. PMID: 28940579.

Patel NU, Felix K, Reimer D, Feldman SR. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017 Sep 29;10:385-391. DOI: 10.2147/CCID.S131727. PMID: 29033598; PMCID: PMC5628677.

Praestegaard M, Steele F, Crutchley N. Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application. Dermatol Ther (Heidelb). 2022 Oct;12(10):2217-2231. DOI: 10.1007/s13555-022-00794-y. Epub 2022 Sep 1. PMID: 36050567; PMCID: PMC9515249.

Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M; trial investigator group. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228-236. DOI: 10.1111/jdv.17734. Epub 2021 Nov 5. PMID: 34628687.

Kircik C, Kircik L. Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study. J Drugs Dermatol. 2023 Mar 1;22(3):271-273. DOI: 10.36849/JDD.7165. PMID: 36877880.

Kircik LH, Draelos ZD, Glick B, Green L, Burgess C. Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis. J Drugs Dermatol. 2024 Aug 1;23(8):607-611. DOI: 10.36849/JDD.7993. PMID: 39093652.

Papp KA, Thoning H, Gerdes S et al. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. J Dermatolog Treat. 2022 Nov;33(7):3005-3013. DOI: 10.1080/09546634.2022.2095330. Epub 2022 Jul 25. PMID: 35875991.

Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res. 2014 Apr;306(3):287-97. DOI: 10.1007/s00403-014-1446-x. Epub 2014 Feb 8. PMID: 24509981; PMCID: PMC3955139.

Feldman SR, Præstegaard M, Andreasen AH, Selmer J, Holm-Larsen T. Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS). Dermatol Ther (Heidelb). 2021 Dec;11(6):2077-2088. DOI: 10.1007/s13555-021-00626-5. Epub 2021 Oct 14. PMID: 34648147; PMCID: PMC8611138.

Elmets CA, Korman NJ, Prater EF et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb;84(2):432-470. DOI: 10.1016/j.jaad.2020.07.087. Epub 2020 Jul 30. PMID: 32738429.

Devaux S, Castela A, Archier E et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:61-7. DOI: 10.1111/j.1468-3083.2012.04525.x. PMID: 22512682.

Ninosu N, Hoelker S, Kappenstein M, Buettner S, Peitsch WK, Schaarschmidt ML. Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness. J Dermatolog Treat. 2023 Dec;34(1):2200570. DOI: 10.1080/09546634.2023.2200570. PMID: 37026416.

Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 Jul;94(1):46-53. PMID: 25101344.

Reich A, Selmer J, Galván J, Trebbien P, Pi-Blanque A, Danø A, Stallknecht SE, Bewley A. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis. Curr Med Res Opin. 2022 Sep;38(9):1521-1529. DOI: 10.1080/03007995.2022.2078099. Epub 2022 Jun 3. PMID: 35575759.

Caldarola G, De Simone C, Moretta G, Poscia A, Peris K. Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients. J Dermatolog Treat. 2017 Dec;28(8):722-725. DOI: 10.1080/09546634.2017.1328100. Epub 2017 May 29. PMID: 28488449.